XML 172 R42.htm IDEA: XBRL DOCUMENT v3.24.2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 10, 2022
USD ($)
Feb. 12, 2022
shares
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 24, 2018
USD ($)
$ / shares
$ / shares
shares
Dec. 31, 2015
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
TWD ($)
Jul. 27, 2023
$ / shares
Feb. 23, 2023
shares
Jul. 01, 2022
Dec. 24, 2018
$ / shares
Collaborative Agreements [Line Items]                                                
Milestone payments royalty percentage                           12.00% 12.00%                  
Collaboration revenue                                       $ 50,000,000        
Cash equivalent                         $ 1,640,000   $ 100,000,000       $ 1,640,000          
Value of new shares issued [1]                           $ 10,698 $ 7,940 $ 3,286                
Common stock price (in New Dollars per share) | $ / shares                       $ 50                        
Common stock per share price | (per share)                           $ 0.001 [1] $ 0.001 [1] $ 0.001 [1]               $ 50
Equity method long term investment (in Shares) | shares                       1,530,000                        
Recognized investment loss                             $ (7,446)   $ 549            
Service agreement eligibility amount $ 3,000,000                                              
Milestone regulatory payment amount period 3 years                                              
Loan amount                           $ 1,000,000 $ 1,000,000                  
Percentage of working capital convertible loan                           5.00% 5.00%                  
Fixed conversion price equal (in Dollars per share) | $ / shares                           $ 1                    
Shares issued (in Shares) | shares                                           5,291,667    
Percentage of net sales                             5.00%                  
Agreement percentage                             15.00% 10.00% 5.00%              
Outstanding amount (in Shares) | shares   5,000,000                                            
Conversion of shares, description                             The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.                  
Previously Reported [Member]                                                
Collaborative Agreements [Line Items]                                                
Cash equivalent                         1,600,000           1,600,000          
Common stock per share price | $ / shares                       $ 1.6                        
Common Stock [Member]                                                
Collaborative Agreements [Line Items]                                                
Common stock per share price | $ / shares                       $ 1.64                 $ 0.001      
BioLite Taiwan [Member]                                                
Collaborative Agreements [Line Items]                                                
Collaboration revenue                                     50,000,000          
Outstanding amount (in Shares) | shares                             5,000,000   5,000,000              
BHK Co-Development Agreement [Member]                                                
Collaborative Agreements [Line Items]                                                
Milestone payment                   $ 31,649,000 $ 10,000,000                          
Description of payment settlement                           ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                  
Upfront cash payment                         $ 1,000,000           1,000,000          
Data and development percentage                         10.00%                      
Total cash amount                 $ 1,000,000       $ 10,000,000                      
BHK Collaborative Agreements [Member] | BioLite Taiwan [Member]                                                
Collaborative Agreements [Line Items]                                                
Cash equivalent                         $ 1,640,000           $ 1,640,000          
Co-Dev Agreement [Member]                                                
Collaborative Agreements [Line Items]                                                
Data and development percentage                           50.00% 50.00%                  
Cash amount               $ 3,000,000             $ 3,000,000                  
Addition cash payment                           $ 3,000,000 $ 3,000,000                  
Additional paid-in capital           $ 3,000,000                                    
Cash received           450,000                                    
Rgene Corporation [Member]                                                
Collaborative Agreements [Line Items]                                                
Value of new shares issued                       $ 2,550,000                        
Collaborative Agreement [Member]                                                
Collaborative Agreements [Line Items]                                                
Data and development percentage                           50.00% 50.00%                  
Total cash amount         $ 3,000,000                                      
Cash amount                           $ 3,000,000 $ 3,000,000                  
Licensing rights             $ 3,000,000                                  
Research and development expense           $ 3,000,000                                    
BioFirst Corporation Purchase Agreement [Member]                                                
Collaborative Agreements [Line Items]                                                
Shares issued (in Shares) | shares     414,702 428,571                                        
Common stock consideration     $ 2,902,911 $ 3,000,000                                        
Rgene Corporation [Member]                                                
Collaborative Agreements [Line Items]                                                
Ownership percentage                           26.65% 26.65% 26.65%                
Ownership percentage                           12.80%                 12.80%  
Rgene Corporation [Member] | Service Agreements [Member]                                                
Collaborative Agreements [Line Items]                                                
Ownership percentage                           31.62% 31.62%                  
Rgene Corporation [Member] | Co-Dev Agreement [Member]                                                
Collaborative Agreements [Line Items]                                                
Ownership percentage                           6.40% 6.40%                  
Rgene Studies [Member]                                                
Collaborative Agreements [Line Items]                                                
Ownership percentage                           20.00%                    
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.